Efficacy and Safety of Remdesivir over Two Waves of the SARS-CoV-2 Pandemic
The aim of this study is to describe the features, the outcomes, and the clinical issues related to Remdesivir administration of a cohort of 220 patients (pts) with COVID-19 hospitalized throughout the last two pandemic waves in Italy. One hundred and nine pts were enrolled from 1 September 2020, to...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/10/12/1477 |
| _version_ | 1797506892915802112 |
|---|---|
| author | Mariacristina Poliseno Crescenzio Gallo Donatella Concetta Cibelli Graziano Antonio Minafra Irene Francesca Bottalico Serena Rita Bruno Maria Luca D’Errico Laura Montemurro Marianna Rizzo Lucia Barbera Giacomo Emanuele Custodero Antonella La Marca Donatella Lo Muzio Anna Miucci Teresa Antonia Santantonio Sergio Lo Caputo |
| author_facet | Mariacristina Poliseno Crescenzio Gallo Donatella Concetta Cibelli Graziano Antonio Minafra Irene Francesca Bottalico Serena Rita Bruno Maria Luca D’Errico Laura Montemurro Marianna Rizzo Lucia Barbera Giacomo Emanuele Custodero Antonella La Marca Donatella Lo Muzio Anna Miucci Teresa Antonia Santantonio Sergio Lo Caputo |
| author_sort | Mariacristina Poliseno |
| collection | DOAJ |
| description | The aim of this study is to describe the features, the outcomes, and the clinical issues related to Remdesivir administration of a cohort of 220 patients (pts) with COVID-19 hospitalized throughout the last two pandemic waves in Italy. One hundred and nine pts were enrolled from 1 September 2020, to 28 February 2021 (Group A) and 111 from 1 March to 30 September 2021 (Group B). Notably, no differences were reported between the two groups neither in the timing of hospitalization. nor in the timing of Remdesivir administration from symptoms onset. Remarkably, a higher proportion of pts with severe COVID-19 was observed in Group B (25% vs. 10%, <i>p</i> < 0.001). At univariate and multivariate analysis, rather than the timing of Remdesivir administration, age, presence of coexisting conditions, D-dimers, and O2 flow at admission correlated positively to progression to non-invasive ventilation, especially for patients in Group B. However, the rate of admission in the Intensive Care Unit and/or death was comparable in the two groups (7% vs. 4%). Negligible variations in serum GOT, GPT, GGT, and eGFR levels were detected. A mean reduction in heart rate was noticed within the first three days of antiviral treatment (<i>p</i> < 0.001). Low rate of ICU admission, high rate of clinical recovery, and good drug safety were observed in COVID-19 patients treated with Remdesivir during two diverse pandemic waves. |
| first_indexed | 2024-03-10T04:39:56Z |
| format | Article |
| id | doaj.art-c4ffb2f22abc4371ab80dff03832c3a5 |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-03-10T04:39:56Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-c4ffb2f22abc4371ab80dff03832c3a52023-11-23T03:30:26ZengMDPI AGAntibiotics2079-63822021-12-011012147710.3390/antibiotics10121477Efficacy and Safety of Remdesivir over Two Waves of the SARS-CoV-2 PandemicMariacristina Poliseno0Crescenzio Gallo1Donatella Concetta Cibelli2Graziano Antonio Minafra3Irene Francesca Bottalico4Serena Rita Bruno5Maria Luca D’Errico6Laura Montemurro7Marianna Rizzo8Lucia Barbera9Giacomo Emanuele Custodero10Antonella La Marca11Donatella Lo Muzio12Anna Miucci13Teresa Antonia Santantonio14Sergio Lo Caputo15Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, ItalyDepartment of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, ItalyUnit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, ItalyUnit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, ItalyUnit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, ItalyUnit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, ItalyUnit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, ItalyUnit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, ItalyUnit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, ItalyUnit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, ItalyUnit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, ItalyUnit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, ItalyUnit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, ItalyUnit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, ItalyUnit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, ItalyUnit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, ItalyThe aim of this study is to describe the features, the outcomes, and the clinical issues related to Remdesivir administration of a cohort of 220 patients (pts) with COVID-19 hospitalized throughout the last two pandemic waves in Italy. One hundred and nine pts were enrolled from 1 September 2020, to 28 February 2021 (Group A) and 111 from 1 March to 30 September 2021 (Group B). Notably, no differences were reported between the two groups neither in the timing of hospitalization. nor in the timing of Remdesivir administration from symptoms onset. Remarkably, a higher proportion of pts with severe COVID-19 was observed in Group B (25% vs. 10%, <i>p</i> < 0.001). At univariate and multivariate analysis, rather than the timing of Remdesivir administration, age, presence of coexisting conditions, D-dimers, and O2 flow at admission correlated positively to progression to non-invasive ventilation, especially for patients in Group B. However, the rate of admission in the Intensive Care Unit and/or death was comparable in the two groups (7% vs. 4%). Negligible variations in serum GOT, GPT, GGT, and eGFR levels were detected. A mean reduction in heart rate was noticed within the first three days of antiviral treatment (<i>p</i> < 0.001). Low rate of ICU admission, high rate of clinical recovery, and good drug safety were observed in COVID-19 patients treated with Remdesivir during two diverse pandemic waves.https://www.mdpi.com/2079-6382/10/12/1477remdesivirCOVID-19 wavesreal life-study |
| spellingShingle | Mariacristina Poliseno Crescenzio Gallo Donatella Concetta Cibelli Graziano Antonio Minafra Irene Francesca Bottalico Serena Rita Bruno Maria Luca D’Errico Laura Montemurro Marianna Rizzo Lucia Barbera Giacomo Emanuele Custodero Antonella La Marca Donatella Lo Muzio Anna Miucci Teresa Antonia Santantonio Sergio Lo Caputo Efficacy and Safety of Remdesivir over Two Waves of the SARS-CoV-2 Pandemic Antibiotics remdesivir COVID-19 waves real life-study |
| title | Efficacy and Safety of Remdesivir over Two Waves of the SARS-CoV-2 Pandemic |
| title_full | Efficacy and Safety of Remdesivir over Two Waves of the SARS-CoV-2 Pandemic |
| title_fullStr | Efficacy and Safety of Remdesivir over Two Waves of the SARS-CoV-2 Pandemic |
| title_full_unstemmed | Efficacy and Safety of Remdesivir over Two Waves of the SARS-CoV-2 Pandemic |
| title_short | Efficacy and Safety of Remdesivir over Two Waves of the SARS-CoV-2 Pandemic |
| title_sort | efficacy and safety of remdesivir over two waves of the sars cov 2 pandemic |
| topic | remdesivir COVID-19 waves real life-study |
| url | https://www.mdpi.com/2079-6382/10/12/1477 |
| work_keys_str_mv | AT mariacristinapoliseno efficacyandsafetyofremdesivirovertwowavesofthesarscov2pandemic AT crescenziogallo efficacyandsafetyofremdesivirovertwowavesofthesarscov2pandemic AT donatellaconcettacibelli efficacyandsafetyofremdesivirovertwowavesofthesarscov2pandemic AT grazianoantoniominafra efficacyandsafetyofremdesivirovertwowavesofthesarscov2pandemic AT irenefrancescabottalico efficacyandsafetyofremdesivirovertwowavesofthesarscov2pandemic AT serenaritabruno efficacyandsafetyofremdesivirovertwowavesofthesarscov2pandemic AT marialucaderrico efficacyandsafetyofremdesivirovertwowavesofthesarscov2pandemic AT lauramontemurro efficacyandsafetyofremdesivirovertwowavesofthesarscov2pandemic AT mariannarizzo efficacyandsafetyofremdesivirovertwowavesofthesarscov2pandemic AT luciabarbera efficacyandsafetyofremdesivirovertwowavesofthesarscov2pandemic AT giacomoemanuelecustodero efficacyandsafetyofremdesivirovertwowavesofthesarscov2pandemic AT antonellalamarca efficacyandsafetyofremdesivirovertwowavesofthesarscov2pandemic AT donatellalomuzio efficacyandsafetyofremdesivirovertwowavesofthesarscov2pandemic AT annamiucci efficacyandsafetyofremdesivirovertwowavesofthesarscov2pandemic AT teresaantoniasantantonio efficacyandsafetyofremdesivirovertwowavesofthesarscov2pandemic AT sergiolocaputo efficacyandsafetyofremdesivirovertwowavesofthesarscov2pandemic |